COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow

被引：2081

作者：

Bikdeli, Behnood ^{[1
,2
,3
]}

Madhavan, Mahesh V. ^{[1
,3
]}

Jimenez, David ^{[4
,5
]}

Chuich, Taylor ^{[1
]}

Dreyfus, Isaac ^{[1
]}

Driggin, Elissa ^{[1
]}

Der Nigoghossian, Caroline ^{[1
]}

Ageno, Walter ^{[6
]}

Madjid, Mohammad ^{[7
]}

Guo, Yutao ^{[8
]}

Tang, Liang V. ^{[9
]}

Hu, Yu ^{[9
]}

Giri, Jay ^{[10
,11
,12
]}

Cushman, Mary ^{[13
]}

Quere, Isabelle ^{[14
]}

Dimakakos, Evangelos P. ^{[15
]}

Gibson, C. Michael ^{[16
,17
]}

Lippi, Giuseppe ^{[18
]}

Favaloro, Emmanuel J. ^{[19
,20
]}

Fareed, Jawed ^{[21
]}

Caprini, Joseph A. ^{[22
]}

Tafur, Alfonso J. ^{[22
,23
]}

Burton, John R. ^{[1
]}

Francese, Dominic P. ^{[3
]}

Wang, Elizabeth Y. ^{[1
]}

Falanga, Anna ^{[24
]}

McLintock, Claire ^{[25
]}

Hunt, Beverley J. ^{[26
]}

Spyropoulos, Alex C. ^{[27
]}

Barnes, Geoffrey D. ^{[28
,29
]}

Eikelboom, John W. ^{[30
]}

Weinberg, Ido ^{[16
,31
]}

Schulman, Sam ^{[32
,33
,34
]}

Carrier, Marc ^{[35
]}

Piazza, Gregory ^{[15
,16
]}

Beckman, Joshua A. ^{[37
]}

Steg, Gabriel ^{[38
,39
,40
]}

Stone, Gregg W. ^{[3
,41
]}

Rosenkranz, Stephan ^{[42
]}

Goldhaber, Samuel Z. ^{[16
,36
]}

Parikh, Sahil A. ^{[1
,3
]}

Monreal, Manuel ^{[43
]}

Krumholz, Harlan M. ^{[2
,44
,45
]}

Konstantinides, Stavros V. ^{[46
]}

Weitz, Jeffrey I. ^{[33
,34
]}

Lip, Gregory Y. H. ^{[47
,48
]}

机构：

[1] Columbia Univ, Irving Med Ctr, NewYork Presbyterian Hosp, 622 West 168th St,PH 3-347, New York, NY 10032 USA

[2] Yale Sch Med, Ctr Outcomes Res & Evaluat CORE, New Haven, CT USA

[3] Cardiovasc Res Fdn, Clin Trials Ctr, New York, NY USA

[4] Univ Alcala, Ctr Invest Biomed Red Enfermedades Resp, Inst Ramon Y Cajal Invest Sanitaria, Hosp Ramon y Cajal,Resp Dept, Madrid, Spain

[5] Univ Alcala, Ctr Invest Biomed Red Enfermedades Resp, Inst Ramon Y Cajal Invest Sanitaria, Dept Med, Madrid, Spain

[6] Univ Insubria, Dept Med & Surg, Varese, Italy

[7] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Houston, TX 77030 USA

[8] Chinese Peoples Liberat Army Gen Hosp, Dept Cardiol, Beijing, Peoples R China

[9] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Inst Hematol, Wuhan, Peoples R China

[10] Hosp Univ Penn, Div Cardiovasc, 3400 Spruce St, Philadelphia, PA 19104 USA

[11] Univ Penn, Leonard Davis Inst Hlth Econ, Penn Cardiovasc Outcomes Qual & Evaluat Res Ctr, Philadelphia, PA 19104 USA

[12] Corporal Michael J Crescenz VA Med Ctr, Philadelphia, PA USA

[13] Univ Vermont, Med Ctr, Burlington, VT USA

[14] Univ Montpellier, Dept Vasc Med, CHU Montpellier, InnoVTE F CRIN Network, Montpellier, France

[15] Sotiria Gen Hosp Athens, Sch Med, Oncol Unit GPP, Athens, Greece

[16] Harvard Med Sch, Boston, MA 02115 USA

[17] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA

[18] Univ Hosp Verona, Lab Clin Chem & Hematol, Verona, Italy

[19] Westmead Hosp, NSW Hlth Pathol, Inst Clin Pathol & Med Res, Haematol Lab, Westmead, NSW, Australia

[20] Sydney Ctr Thrombosis & Haemostasis, Westmead, NSW, Australia

[21] Loyola Univ, Med Ctr, Chicago, IL 60611 USA

[22] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA

[23] NorthShore Univ Hlth Syst, Dept Med, Div Vasc Med, Skokie, IL USA

[24] Univ Milano Bicocca, Hosp Papa Giovanni XXIII, Dept Immunohematol & Transfus Med, Bergamo, Italy

[25] Auckland City Hosp, Auckland, New Zealand

[26] St Thomas Hosp, London, England

[27] Hofstra Univ, Donald & Barbara Zucker Sch Med Hofstra Northwell, Hempstead, NY 11550 USA

[28] Univ Michigan, Ctr Bioeth & Social Sci Med, Ann Arbor, MI 48109 USA

[29] Univ Michigan, Frankel Cardiovasc Ctr, Ann Arbor, MI 48109 USA

[30] McMaster Univ, Hamilton Hlth Sci, Populat Hlth Res Inst, Hamilton, ON, Canada

[31] Massachusetts Gen Hosp, Boston, MA 02114 USA

[32] IM Sechenov First Moscow State Med Univ, Dept Obstet & Gynecol, Moscow, Russia

[33] McMaster Univ, Hamilton, ON, Canada

[34] Thrombosis & Atherosclerosis Res Inst, Hamilton, ON, Canada

[35] Ottawa Hosp, Res Inst, Ottawa, ON, Canada

[36] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA

[37] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA

[38] Hop Bichat Claude Bernard, AP HP, FACT French Alliance Cardiovasc Trials, INSERM U1148, Paris, France

[39] Univ Paris, Paris, France

[40] Imperial Coll London, Royal Brompton Hosp, London, England

[41] Icahn Sch Med Mt Sinai, Zena & Michael A Wiener Cardiovasc Inst, New York, NY 10029 USA

[42] Univ Cologne, Dept Cardiol, Cologne Cardiovasc Res Ctr, Ctr Heart, Cologne, Germany

[43] Univ Catolica San Antonio Murcia, Hosp Univ Germans Trias & Pujol, Dept Internal Med, Barcelona, Spain

[44] Yale Sch Publ Hlth, Dept Hlth Policy & Adm, New Haven, CT USA

[45] Yale Sch Med, Dept Internal Med, Sect Cardiovasc Med, New Haven, CT USA

[46] Johannes Gutenberg Univ Mainz, Ctr Thrombosis & Hemostasis, Mainz, Germany

[47] Univ Liverpool, Liverpool Heart & Chest Hosp, Liverpool Ctr Cardiovasc Sci, Liverpool, Merseyside, England

[48] Aalborg Univ, Aalborg, Denmark

来源：

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2020年 / 75卷 / 23期

基金：

美国国家卫生研究院;

关键词：

HOSPITALIZED MEDICAL PATIENTS; ACUTE MYOCARDIAL-INFARCTION; HEMATOLOGY; 2018; GUIDELINES; ACUTE RESPIRATORY SYNDROME; ACUTE PULMONARY-EMBOLISM; EXTRACORPOREAL MEMBRANE-OXYGENATION; INTENSIVE-CARE UNIT; VENOUS THROMBOEMBOLISM; ACUTELY ILL; INFLUENZA INFECTION;

D O I：

10.1016/j.jacc.2020.04.031

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Coronavirus disease-2019 (COVID-19), a viral respiratory illness caused by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), may predispose patients to thrombotic disease, both in the venous and arterial circulations, because of excessive inflammation, platelet activation, endothelial dysfunction, and stasis. In addition, many patients receiving antithrombotic therapy for thrombotic disease may develop COVID-19, which can have implications for choice, dosing, and laboratory monitoring of antithrombotic therapy. Moreover, during a time with much focus on COVID-19, it is critical to consider how to optimize the available technology to care for patients without COVID-19 who have thrombotic disease. Herein, the authors review the current understanding of the pathogenesis, epidemiology, management, and outcomes of patients with COVID-19 who develop venous or arterial thrombosis, of those with pre-existing thrombotic disease who develop COVID-19, or those who need prevention or care for their thrombotic disease during the COVID-19 pandemic. (J Am Coll Cardiol 2020;75:2950-73) (c) 2020 by the American College of Cardiology Foundation.

引用

页码：2950 / 2973

页数：24

共 153 条

[1] Extra-corporeal membrane oxygenation and outcomes in massive pulmonary embolism: Two eras at an urban tertiary care hospital [J].

Ain, David L. ;

Albaghdadi, Mazen ;

Giri, Jay ;

Abtahian, Farhad ;

Jaff, Michael R. ;

Rosenfield, Kenneth ;

Roy, Nathalie ;

Villavicencio-Theoduloz, Mauricio ;

Sundt, Thoralf ;

Weinberg, Ido .

VASCULAR MEDICINE, 2018, 23 (01) :60-64

[2] Searching for High-Risk Venous Thromboembolism Patients Using Risk Scores: Adding to the Heap or Closing a Gap? [J].

Albertsen, Ida Ehlers ;

Nielsen, Peter Bronnum .

THROMBOSIS AND HAEMOSTASIS, 2018, 118 (10) :1686-1687

[3]

Amsterdam EA, 2014, CIRCULATION, V130, P2354, DOI 10.1161/CIR.0000000000000133

[4] Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Interim guidance [J].

不详 .

PEDIATRIA I MEDYCYNA RODZINNA-PAEDIATRICS AND FAMILY MEDICINE, 2020, 16 (01) :9-26

[5]

[Anonymous], HUB STRENGTH EP PREV

[6]

[Anonymous], CARDIOLOGY MAGAZINE

[7]

[Anonymous], IMPL MIT STRAT COMM

[8]

[Anonymous], NICE CLIN GUID 92 VE

[9]

[Anonymous], RED RISK VEN THROMB

[10]

[Anonymous], NOV COR COVID 19

← 1 2 3 4 5 6 7 8 9 10 →